journal
MENU ▼
Read by QxMD icon Read
search

Pulmonary Pharmacology & Therapeutics

journal
https://www.readbyqxmd.com/read/29763659/safety-and-pharmacokinetics-of-budesonide-glycopyrronium-formoterol-fumarate-dihydrate-metered-dose-inhaler-bgf-mdi-in-healthy-adult-subjects-of-japanese-descent
#1
Paul Dorinsky, Paolo DePetrillo, Shahid Siddiqui, Andrea Maes, Colin Reisner
INTRODUCTION: BGF MDI, a budesonide, glycopyrronium, and formoterol fumarate dihydrate triple fixed-dose combination metered dose inhaler formulated using co-suspension delivery technology, is currently in Phase III global development for chronic obstructive pulmonary disease. METHODS: This was a Phase I, randomized, double-blind, placebo-controlled, ascending-dose, crossover study to assess the safety and pharmacokinetic profiles of two doses of BGF MDI in healthy adult subjects of Japanese descent (NCT02197975)...
May 12, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29705620/impact-of-doxofylline-in-copd-a-pair-wise-meta-analysis
#2
Mario Cazzola, Luigino Calzetta, Paola Rogliani, Clive Page, Maria Gabriella Matera
Doxofylline is an effective bronchodilator for relieving airway obstruction in patients with asthma or chronic obstructive pulmonary disease (COPD), and displays a better safety profile with respect to theophylline. Herein, we performed a pair-wise meta-analysis of the currently available data to provide consistent and homogeneous findings on the impact of this xanthine in COPD patients. Results obtained from 820 patients were selected from 20 clinical trials. Meta-regression was performed to examine the source of heterogeneity between-studies and identify potential confounder covariates...
April 26, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29702255/the-role-of-sphingolipid-metabolism-disruption-on-lipopolysaccharide-induced-lung-injury-in-mice
#3
Renata Tiemi Okuro, Mariana Nascimento Machado, Natália Vasconcelos Casquilho, Alcendino Jardim-Neto, Alysson Roncally-Carvalho, Georgia Correa Atella, Walter Araujo Zin
AIM: This study assessed pulmonary outcomes generated by inhibiting key enzymes of sphingolipid metabolism pathways related to ceramide synthesis in a murine model of lung injury induced by lipopolysaccharide (LPS). METHODS: C57BL/6 male adult mice received LPS intratracheally and the expressions of acid sphingomyelinase (ASM), neutral sphingomyelinase (NSM), serine palmitoyl transferase (SPT) and dihydroceramide synthase (DS) were assessed at 2, 4, 6, 12 and 24 h after LPS instillation in lung homogenate (n = 30)...
April 24, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29698781/in-vivo-and-in-vitro-investigation-of-anti-inflammatory-and-mucus-regulatory-activities-of-a-fixed-combination-of-thyme-and-primula-extracts
#4
Jan Seibel, Kirill Kryshen, Judit E Pongrácz, Martin D Lehner
Hypersecretion of viscous mucus is one of the hallmark symptoms of acute and chronic bronchitis and typically develops secondary to an inflammation of the airway epithelium. Bronchipret® TP film-coated tablets (BRO), an herbal medicinal product containing a fixed combination of thyme herb and primula root extracts, has been successfully used clinically for the treatment of acute bronchitis for more than two decades. However, the underlying pharmacological mechanisms of action have not been fully understood so far...
April 23, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29679678/characterisation-of-40-mg-ml-and-100-mg-ml-tobramycin-formulations-for-aerosol-therapy-with-adult-mechanical-ventilation
#5
Jayesh A Dhanani, Patrician Tang, Steven C Wallis, Suzanne L Parker, Preeti Pandey, John F Fraser, Jeremy Cohen, Adrian Barnett, Jason R Roberts, Hak-Kim Chan
BACKGROUND: Preservative-free tobramycin is commonly used as aerosolized therapy for ventilator associated pneumonia. The comparative delivery profile of the formulations of two different concentrations (100 mg/ml and 40 mg/ml) is unknown. This study aims to evaluate the aerosol characteristics of these tobramycin formulations in a simulated adult mechanical ventilation model. METHODS: Simulated adult mechanical ventilation set up and optimal settings were used in the study...
April 18, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29673911/targeting-the-rhoa-rock-pathway-to-regulate-t-cell-homeostasis-in-hypoxia-induced-pulmonary-arterial-hypertension
#6
Cheng Li, Ping-Ping Liu, Dou-Dou Tang, Rong Song, Yi-Qing Zhang, Si Lei, Shang-Jie Wu
BACKGROUND: Hypoxic pulmonary arterial hypertension (PAH) is a crippling disease with limited therapeutic methods. The imbalance of T helper 17 cell (Th17)/regulatory T cell (Treg) plays an important role in the development of Hypoxic PAH. However, whether targeting the ras homolog family member A-Rho kinase (RhoA-ROCK) pathway (activation and inhibition) by lysophosphatidic acid (LPA) and fasudil (FSD) regulate T-cell homeostasis in Hypoxic PAH remain unknown. OBJECTIVE: To examine the effects of LPA and FSD on hypoxic pulmonary vascular remodeling and homeostasis of Th17/Treg cells in Hypoxic PAH...
April 16, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29660401/intravenous-fosfomycin-for-pulmonary-exacerbation-of-cystic-fibrosis-real-life-experience-of-a-large-adult-cf-centre
#7
G Spoletini, M Kennedy, L Flint, T Graham, C Etherington, N Shaw, P Whitaker, M Denton, I Clifton, D Peckham
BACKGROUND: The increased prevalence of multi-drug resistant strains of P.aeruginosa and allergic reactions among adult patients with cystic fibrosis (CF) limits the number of antibiotics available to treat pulmonary exacerbations. Fosfomycin, a unique broad spectrum bactericidal antibiotic, might offer an alternative therapeutic option in such cases. AIM: To describe the clinical efficacy, safety and tolerability of intravenous fosfomycin in combination with a second anti-pseudomonal antibiotic to treat pulmonary exacerbations in adult patients with CF...
April 13, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29653189/overreliance-link-between-asthmatic-subjects-and-short-acting-%C3%AE-2-agonists
#8
LETTER
Luis J Nannini
In this brief communication, it was described the overreliance link generated between a young asthmatic subject and Short Acting Beta agonist (SABA) bronchodilator. It was an attempt to delineate the stages of this conflicting link where predominated the overreliance on SABA that might be one of the main circumstances surrounding near fatal asthma attack. New approach is needed from international guidelines to avoid development of such a problematic link between asthmatic subjects and SABA.
April 10, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29635073/modeling-and-optimization-of-nebulizers-performance-in-non-invasive-ventilation-using-different-fill-volumes-comparative-study-between-vibrating-mesh-and-jet-nebulizers
#9
Haitham Saeed, Ahmed M A Ali, Ahmed A Elberry, Abeer Salah Eldin, Hoda Rabea, Mohamed E A Abdelrahim
BACKGROUNDS: Substituting nebulisers by another, especially in non-invasive ventilation (NIV), involves many process-variables, e.g. nebulizer-type and fill-volume of respirable-dose, which might affect patient optimum-therapy. The aim of the present work was to use neural-networks and genetic-algorithms to develop performance-models for two different nebulizers. METHODS: In-vitro, ex-vivo and in-vivo models were developed using input-variables including nebulizer-type [jet nebulizer (JN) and vibrating mesh nebulizer (VMN)] fill-volumes of respirable dose placed in the nebulization chamber with an output-variable e...
April 7, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29627483/effects-of-fluticasone-propionate-and-budesonide-on-the-expression-of-immune-defense-genes-in-bronchial-epithelial-cells
#10
M van den Berge, M R Jonker, A Miller-Larsson, D S Postma, I H Heijink
BACKGROUND: COPD patients have increased risk of pneumonia when treated with fluticasone propionate (FP), whereas this is generally not the case with budesonide (BUD) treatment. We hypothesized that BUD and FP differentially affect the expression of immune defense genes. METHODS: Human bronchial epithelial 16HBE cells and air-liquid interface (ALI)-cultured primary bronchial epithelial cells (PBECs) were pre-treated with clinically equipotent concentrations of BUD or FP (0...
April 5, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29627482/assessment-of-statin-induced-interstitial-pneumonia-in-patients-treated-for-hyperlipidemia-using-a-health-insurance-claims-database-in-japan
#11
Kenji Momo, Akiko Takagi, Atsuko Miyaji, Masayoshi Koinuma
PURPOSE: This study aimed to determine the frequency and risk factors for statin-induced interstitial pneumonia (IP). METHOD: We conducted a retrospective cohort study using a large Japanese health insurance claims database. We determined the statin-induced IP incidence in patients treated with statins for hyperlipidemia (n = 194,814) with 12-month screening and 3-month observation periods. Statin-induced IP was defined as: (1) diagnosis with IP (ICD-10 codes: J70...
April 5, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29626633/serum-lipoproteins-are-not-associated-with-the-severity-of-asthma
#12
Federica Scaduto, Rosaria Vincenza Giglio, Alida Benfante, Dragana Nikolic, Giuseppe Montalto, Manfredi Rizzo, Nicola Scichilone
BACKGROUND: Asthma is a chronic inflammatory disorder of the bronchi with a complicated and largely unknown pathogenesis. In this context, an emerging role is attributed to the apolipoproteins which serve as structural components of plasma lipoproteins. Low density lipoproteins (LDL) may be involved in the inflammatory pathways of the asthmatic airways; in particular, small dense LDL (sdLDL) particles were associated with increased oxidative susceptibility compared to medium and large sized LDL...
April 4, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29621625/ciprofloxacin-dry-powder-for-inhalation-ciprofloxacin-dpi-technical-design-and-features-of-an-efficient-drug-device-combination
#13
REVIEW
Pamela J McShane, Jeffry G Weers, Thomas E Tarara, Alfred Haynes, Preeti Durbha, Danforth P Miller, Tobias Mundry, Elisabeth Operschall, J Stuart Elborn
Bronchiectasis is a chronic respiratory disease with heterogeneous etiology, characterized by a cycle of bacterial infection and inflammation, resulting in increasing airway damage. Exacerbations are an important cause of morbidity and are strongly associated with disease progression. Many patients with bronchiectasis suffer from two or more exacerbations per year. However, there are no approved therapies to reduce or delay exacerbations in this patient population. Ciprofloxacin DPI is in development as a long-term, intermittent therapy to reduce exacerbations in patients with non-cystic fibrosis (CF) bronchiectasis and evidence of respiratory pathogens...
April 2, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29621624/astilbin-ameliorates-pulmonary-fibrosis-via-blockade-of-hedgehog-signaling-pathway
#14
Jie Zhang, Hanchen Liu, Chenguang Song, Jinjin Zhang, Youlei Wang, Changjun Lv, Xiaodong Song
BACKGROUND AND OBJECTIVE: The nature of pulmonary fibrosis involves inadequate repair of the epithelial cell barrier accompanied by impaired regulation of the fibroblast. Moreover, pulmonary fibrosis currently lacks an effective therapeutic drug. This study targets the protection of the epithelial cell and fibroblast to identify a novel, potentially therapeutic drug (i.e., astilbin). METHODS: In this study, the cytotoxicity of astilbin was firstly detected using CCK-8...
April 2, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29609004/emerging-biological-therapies-for-treating-chronic-obstructive-pulmonary-disease-a-pairwise-and-network-meta-analysis
#15
Paola Rogliani, Maria Gabriella Matera, Ermanno Puxeddu, Marco Mantero, Francesco Blasi, Mario Cazzola, Luigino Calzetta
Inflammation in chronic obstructive pulmonary disease (COPD) is often corticosteroid resistant and, thus, alternative anti-inflammatory approaches are needed. Since it is still not clear whether blocking specific pro-inflammatory factors may provide clinical benefit in COPD, we have performed a meta-analysis to quantify the impact of monoclonal antibodies (mABs) targeting the cytokine/chemokine-mediated inflammation in COPD. A pairwise and network meta-analyses were performed by extracting data from randomized clicnial trials on COPD concerning the impact of mABs vs...
March 30, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29605286/pulmonary-hypertension-in-patients-with-interstitial-lung-disease
#16
REVIEW
Theodoros Karampitsakos, Argyrios Tzouvelekis, Serafeim Chrysikos, Demosthenes Bouros, Iraklis Tsangaris, Wassim H Fares
Interstitial lung diseases (ILDs) comprise a broad and heterogeneous group of more than two hundred diseases with common functional characteristics. Their diagnosis and management require a multidisciplinary approach. This multidisciplinary approach involves the assessment of comorbid conditions including pulmonary hypertension (PH) that exerts a dramatic impact on survival. The current World Health Organization (WHO) classification of PH encompasses many of the interstitial lung diseases into WHO Group 3, while sarcoidosis, Pulmonary Langerhans Cell Histiocytosis and lymphangioleiomyomatosis are placed into WHO Group 5 as diseases with unclear or multifactorial mechanisms...
March 29, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29544728/the-pharmacokinetics-of-three-doses-of-budesonide-glycopyrronium-formoterol-fumarate-dihydrate-metered-dose-inhaler-compared-with-active-controls-a-phase-i-randomized-single-dose-crossover-study-in-healthy-adults
#17
Patrick Darken, Paolo DePetrillo, Colin Reisner, Earl St Rose, Paul Dorinsky
The budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) is an inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2 -agonist fixed-dose combination formulated with innovative co-suspension delivery technology that is in clinical development for the treatment of chronic obstructive pulmonary disease (COPD). This randomized, Phase I, single-dose, six-treatment, four-period, crossover study (NCT01980615) examined the pharmacokinetic (PK) and safety profile of three doses of BGF MDI (320/14...
March 12, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29567116/cardiovascular-safety-profile-of-a-fixed-dose-combination-of-glycopyrrolate-and-formoterol-fumarate-delivered-via-metered-dose-inhaler-using-co-suspension-delivery-technology
#18
Gary T Ferguson, Colin Reisner, James Pearle, Paolo DePetrillo, Andrea Maes, Ubaldo J Martin
BACKGROUND: Glycopyrrolate/formoterol fumarate (GFF) metered dose inhaler (MDI) is a fixed-dose combination of the long-acting muscarinic antagonist (LAMA), glycopyrrolate (GP), and the long-acting β2 -agonist (LABA), formoterol fumarate (FF), delivered via metered dose inhaler using innovative co-suspension delivery technology. Here we report the results of two studies that examined the cardiovascular safety of GFF MDI. METHODS: The thorough QT (TQT) study was a Phase I, randomized, double-blind, single-dose, crossover study to assess GFF MDI 18/9...
April 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29501590/modeling-of-pharmacokinetics-efficacy-and-hemodynamic-effects-of-macitentan-in-patients-with-pulmonary-arterial-hypertension
#19
Andreas Krause, Jochen Zisowsky, Jasper Dingemanse
BACKGROUND: Macitentan is the first endothelin receptor antagonist with demonstrated efficacy on morbidity and mortality in pulmonary arterial hypertension (PAH) in the pivotal study SERAPHIN. METHODS: The pharmacokinetics (PK) of macitentan and its active metabolite, ACT-132577, were characterized in a population model. Efficacy and hemodynamics (pharmacodynamics, PD) were related to PK based on PK/PD modeling. RESULTS: Sex, age, and body weight influenced the PK to a statistically significant extent...
April 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29474893/better-airway-resistance-reduction-profile-in-intubated-copd-patients-by-personalized-bronchodilator-dosing-a-pilot-randomized-control-trial
#20
Shin-Hwar Wu, Lih-Jen Shyu, Chin-Hsing Li, Chao-Hung Yu, Huang-Chi Chen, Chew-Teng Kor, Chu-Hsien Wang, Kai-Huang Lin
INTRODUCTION: The optimal dose of inhaled metered-dose bronchodilators for intubated patients with chronic obstructive pulmonary disease (COPD) is unknown. In this study, we proposed a bronchodilator dosing schedule based on an individual's airway resistance (Raw ) and tested its efficacy in reducing Raw . METHODS: A total of 51 newly admitted patients with invasively ventilated COPD were randomly assigned to receive personalized or fixed bronchodilator dosing. Personal target Raw was defined by measuring each individual's Raw after maximal pharmacologic bronchodilatation...
April 2018: Pulmonary Pharmacology & Therapeutics
journal
journal
32865
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"